A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.
Launched by BIO PRODUCTS LABORATORY · Sep 24, 2014
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with moderate to severe Haemophilia B (≤5% baseline Factor IX level) due to undergo major surgery, previously treated patients, at least 16 years of age without inhibitors, currently receiving Factor IX concentrate.
- Exclusion Criteria:
- • -
About Bio Products Laboratory
Bio Products Laboratory (BPL) is a leading global biopharmaceutical company specializing in the development, manufacture, and distribution of immunoglobulin therapies and other bioproducts derived from human plasma. With a commitment to innovation and quality, BPL focuses on addressing unmet medical needs through advanced research and clinical trials. The company adheres to stringent regulatory standards, ensuring the safety and efficacy of its products while striving to improve patient outcomes across a range of conditions. Leveraging a robust pipeline and state-of-the-art facilities, BPL is dedicated to enhancing healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southampton, , United Kingdom
Basingstoke, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials